A Phase 1, Open-label Study to Assess the Absorption, Metabolism, and Excretion, Including the Mass Balance, of a Single Oral Dose of [14C]-Etrumadenant in Healthy Male Subjects
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Etrumadenant (Primary)
- Indications Bladder cancer; Breast cancer; Cancer; Colorectal cancer; Endometrial cancer; Gastrointestinal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Rectal cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Arcus Biosciences
Most Recent Events
- 09 Jul 2022 Status changed from active, no longer recruiting to completed.
- 28 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jul 2022.
- 28 Jun 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jul 2022.